GRAIL big action: 120,000 women participate in early breast cancer diagnosis

Recently, the highly regarded new company GRAIL announced that it will launch a large-scale clinical trial to develop its core liquid biopsy technology. According to the plan, this clinical trial will recruit up to 120,000 women and develop and validate an early diagnosis of breast cancer by analyzing their blood-free nucleic acids (cfNA).

Since its inception last year, GRAIL has attracted a lot of attention from the industry. In January last year, GRAIL completed a Series A round of financing led by Illumina and renowned venture capital ARCH Venture Partners, which received up to $100 million in funding. After just over a year, GRAIL raised $900 million in Series B financing. Using these funds, GRAIL has launched the "Circulating Cell-Free Genome Atlas Study" (CCGA) project to understand the similarities and differences between cfNA in cancer patients and healthy people, thereby assisting subsequent research and products. Development. The STRIVE clinical trial launched today will further train and validate an artificial intelligence-based approach for breast cancer detection. In addition, this clinical trial is expected to develop methods for early diagnosis of other cancers.

GRAIL大动作:12万女性参与早期乳腺癌诊断

Breast cancer targeted at this clinical trial is one of the most common cancers among women worldwide. Although compared to a decade ago, the current treatment for breast cancer has made rapid progress, but in the United States alone, nearly 40,000 people will die of this disease. This is partly due to the refractory treatment of advanced breast cancer – for patients with stage 1 or 2 breast cancer, their 5-year survival rates are as high as 100% and 91%, respectively. However, once the cancer progresses to stage 4, the 5-year survival rate plummets to 22%. Therefore, being able to diagnose a condition early in breast cancer is critical to the patient's life.

GRAIL大动作:12万女性参与早期乳腺癌诊断

▲ Dr. Ken Drazan, Chief Commercial Officer of GRAIL, mentioned at the 2017 WuXi PharmaTech Global Forum that early diagnosis is “the best way to save millions of lives”

Fresh Frozen Yellow Croaker

fresh frozen yellow croaker

Frozen Yellow Croaker,Delicious Yellow Croaker,Fresh Frozen Yellow Croaker,Delicious Fresh Frozen Yellow Croaker

Zhoushan Junwei Aquatic Products Co., Ltd. , https://www.junweiaquatic-intl.com

Posted on